Clinical trials: Plaque
Atopic Dermatitis, Plaque Psoriasis
A Study to Learn About The Study Medicine (PF-07038124) In Patients With Mild To Moderate Atopic Dermatitis Or Mild To Severe Plaque Psoriasis.
The purpose of this clinical trial is to learn about the safety, how well the study medicine works, extent to which side effects can be tolerated, and how the study medicine is changed and eliminated from your body after you…
- Trial name
- NCT05375955
- Testing
- PF-07038124 ointment 0.01%, Vehicle ointment, PF-07038124 ointment 0.03%
- Where
- 39 sites in United States, Canada and 2 more
- Volunteers
- 263 people
- Sponsor
- Pfizer
Psoriasis
Efficacy and Safety of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis
The two objectives of this study were to evaluate long-term efficacy and safety of adalimumab treatment in participants who had moderate to severe chronic plaque psoriasis and to evaluate the effectiveness of adalimumab…
- Trial name
- NCT00195676
- Testing
- adalimumab
- Where
- 104 sites in United States, Austria and 8 more
- Volunteers
- 1,469 people
- Sponsor
- Abbott
Subjective Memory Loss in Older Persons
Study of the Effects of Cerefolin NAC on Inflammation Blood Markers in Older Individuals With Memory Complaints
The purpose of this six-month research study is to determine if Cerefolin NAC reduces levels of substances in the blood that may be associated with thinking ability and the health of brain cells in subjects with memory concerns…
- Trial name
- NCT00597376
- Testing
- Cerefolin NAC (a medical food)
- Where
- United States
- Volunteers
- 104 people
- Sponsor
- Rush University Medical Center
Plaque Psoriasis
Safety and Efficacy of IDP-122 in Participants With Plaque Psoriasis
This study is to evaluate the safety and efficacy of a topical lotion when applied once daily to adult participants with moderate to severe plaque psoriasis (defined as an Investigator's Global Assessment [IGA] score of 3 or 4).
- Trial name
- NCT02515097
- Testing
- IDP-122 Lotion, IDP-122 Vehicle Lotion
- Where
- 15 sites in United States
- Volunteers
- 213 people
- Sponsor
- Bausch Health Americas, Inc.
Psoriasis
Effectiveness and Safety of BMS-986165 Compared to Placebo and Active Comparator in Participants With Psoriasis
The purpose of this study is to investigate the experimental medication BMS-986165 compared to placebo and a currently available treatment in participants with moderate to severe plaque psoriasis.
- Trial name
- POETYK-PSO-1 (NCT03624127)
- Testing
- BMS-986165, Apremilast
- Where
- 165 sites in United States, Canada and 9 more
- Volunteers
- 666 people
- Sponsor
- Bristol-Myers Squibb
Gingivitis
A Clinical Study to Evaluate the Efficacy of a Range of Dental/Denture Products for Improved Oral Health in Partial Denture Wearers
The purpose of this study is to investigate the effectiveness of usage of a range of oral products (toothpaste, mouth rinse, denture cleanser) on the oral health of partial denture wearers compared to existing oral hygiene…
- Trial name
- NCT04290624
- Testing
- Experimental Dentifrice: Stannous Fluoride, COREGA Denture Foaming Cleanser, Mouth rinse: Sodium Fluoride
- Where
- United Kingdom
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- HALEON
Coronary Artery Disease
Evaluation of a Combined Near Infrared Spectroscopy (NIRS) and Intravascular Ultrasound (IVUS) Catheter for Detection of Lipid Rich Plaque
The purpose of this study is to learn more about lipid rich plaque using Near Infrared Spectroscopy (NIRS)/Intravascular Ultrasound (IVUS) imaging in patients who have had coronary artery stenting and Optical coherence tomography…
- Trial name
- NCT01506960
- Testing
- InfraReDx Lipiscan IVUS
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- Massachusetts General Hospital
Plaque Psoriasis
Study to Assess the Potential for Adrenal Suppression Following Treatment With DSXS in Patients With Plaque Psoriasis
An open label, safety study to assess the potential for adrenal suppression following maximal use treatment with DSXS administered twice daily for 28 days in patients with moderate to severe plaque psoriasis.
- Trial name
- NCT02601469
- Testing
- DSXS
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Breast Cancer
Amyloid Plaque Deposition in Chemotherapy-Induced Cognitive Impairment
The initial goal of the investigators interdisciplinary group of imagers, oncologists, neurologists, neuro-psychologists, and biostatisticians is to obtain proof of concept pilot data for eventual submission of a National Cancer…
- Trial name
- NCT02317783
- Testing
- [18F]Flutemetamol, [18F]fluoro-2-deoxy-D-glucose (FDG), Functional Magnetic Resonance Imaging (fMRI)
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Utah
Plaque Psoriasis
Long-Term Safety of IDP-118 Lotion in the Treatment of Plaque Psoriasis
The objective of this study is to evaluate the long-term safety of IDP-118 lotion.
- Trial name
- NCT02462083
- Testing
- IDP-118 Lotion
- Where
- 46 sites in United States
- Volunteers
- 555 people
- Sponsor
- Bausch Health Americas, Inc.
Psoriasis
Study to Compare Efficacy and Safety of ABP 501 and Adalimumab (HUMIRA®) in Adults With Moderate to Severe Plaque Psoriasis
The purpose of this research study is to compare the efficacy and safety of ABP 501 and adalimumab (HUMIRA®) in adults with plaque psoriasis.
- Trial name
- NCT01970488
- Testing
- Adalimumab, ABP 501
- Where
- 3 sites in Australia, Canada and 1 more
- Volunteers
- 350 people
- Sponsor
- Amgen
Plaque Psoriasis
A Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous Tildrakizumab (SCH 900222/MK-3222) in Participants With Moderate-to-Severe Chronic Plaque Psoriasis Followed by a Long-term Extension Study (MK-3222-011)
This study is being conducted to evaluate the efficacy and safety/tolerability of tildrakizumab (SCH 900222/MK-3222) in a population of participants with moderate-to-severe plaque psoriasis.
- Trial name
- reSURFACE 2 (NCT01729754)
- Testing
- Tildrakizumab 200 mg, Tildrakizumab 100 mg, Etanercept 50 mg
- Volunteers
- 1,090 people
- Sponsor
- Sun Pharmaceutical Industries Limited
Plaque Psoriasis
A Study of JNJ-77242113 in Participants With Moderate-to-severe Plaque Psoriasis
Th purpose of the study is to evaluate the dose response of JNJ-77242113 in efficacy at Week 16 in participants with moderate-to-severe plaque psoriasis.
- Trial name
- FRONTIER 1 (NCT05223868)
- Testing
- JNJ-77242113
- Where
- 76 sites in United States, Canada and 8 more
- Volunteers
- 255 people
- Sponsor
- Janssen Research & Development, LLC
Psoriasis
Secukinumab Study in PSOriasis Exploring pruRITUS Intensity and Lesional Biomarkers
The study is designed to explore the kinetics of psoriasis symptoms, pruritus intensity and lesional biomarkers.
- Trial name
- PSORITUS (NCT02362789)
- Testing
- Secukinumab
- Where
- 19 sites in Germany
- Volunteers
- 132 people
- Sponsor
- Novartis Pharmaceuticals
Psoriasis
A Study to Assess Safety and Efficacy of Risankizumab Using a New Formulation in Participants With Moderate to Severe Plaque Psoriasis
The primary objective of this study was to evaluate the safety and efficacy of risankizumab (150 mg/mL) administered by prefilled syringe (PFS) for the treatment of adult participants with moderate to severe plaque psoriasis.
- Trial name
- NCT03875482
- Testing
- Risankizumab
- Where
- 43 sites in United States, Puerto Rico
- Volunteers
- 157 people
- Sponsor
- AbbVie
Mild Cognitive Impairment
Lithium As a Treatment to Prevent Impairment of Cognition in Elders
Alzheimer's disease (AD) is the most common cause of dementia in adults 65 years and older. AD leads to a complete loss of memory and independent function, and presently there is no cure.
- Trial name
- LATTICE (NCT03185208)
- Testing
- Lithium Carbonate
- Where
- United States
- Volunteers
- 83 people
- Sponsor
- Ariel Gildengers, MD
Psoriasis
Immunologic Response to Secukinumab in Plaque Psoriasis
This is a single-arm, open-label study, which will examine the effect of secukinumab on the immunologic and genetic environment within psoriatic lesions.
- Trial name
- NCT02592018
- Testing
- Secukinumab
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of California, San Francisco
Nail Psoriasis, Plaque Psoriasis
A Study to Evaluate the Safety and Efficacy of Adalimumab in Subjects With Chronic Plaque Psoriasis and Nail Psoriasis
This study is being conducted to assess the safety and efficacy of adalimumab in participants with nail psoriasis.
- Trial name
- NCT02016482
- Testing
- Adalimumab
- Volunteers
- 217 people
- Sponsor
- AbbVie
Acute Coronary Syndrome
MDCO-216 Infusions Leading to Changes in Atherosclerosis: A Novel Therapy in Development to Improve Cardiovascular Outcomes - Proof of Concept Intravascular Ultrasound (IVUS), Lipids, and Other Surrogate Biomarkers Trial
This study will be a proof-of-concept, placebo-controlled, double-blind, randomized trial in participants with a recent acute coronary syndrome (ACS) to evaluate the efficacy, pharmacokinetics, safety, tolerability, disease…
- Trial name
- PILOT (NCT02678923)
- Testing
- MDCO-216
- Where
- 20 sites in Canada, Czechia and 3 more
- Volunteers
- 126 people
- Sponsor
- The Medicines Company
Psoriasis
Efficacy and Safety of Etanercept 50 mg Once Weekly Plus As Needed Topical Agent in Moderate to Severe Plaque Psoriasis
To estimate the difference in effectiveness between treatment with etanercept 50 mg twice weekly (BIW) and treatment with etanercept 50 mg once weekly (QW) plus an as needed (PRN) topical agent for 12 weeks in adults with…
- Trial name
- REFINE (NCT01313221)
- Testing
- etanercept, Topical agents
- Where
- 24 sites in Canada
- Volunteers
- 310 people
- Sponsor
- Amgen